Udvalget for Humanmedicinske Lægemidler (CHMP) var af den opfattelse, at fordelene ved Viraferon Læ
The Committee for Medicinal Products for Human Use (CHMP) decided that Viraferon’ s benefits are greater than its risks for the treatment of chronic hepatitis B and C.